Reuters logo
BRIEF-Versartis Inc presents 3-year somavaratan safety and efficacy data
May 22, 2017 / 12:40 PM / 6 months ago

BRIEF-Versartis Inc presents 3-year somavaratan safety and efficacy data

May 22 (Reuters) - Versartis Inc

* Versartis presents 3-year somavaratan safety and efficacy data and pediatric program baseline demographics at the 19th European congress of endocrinology

* Three-year results support 3.5 mg/kg twice-monthly dose regimen being used in ongoing phase 3 velocity trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below